Products
Adezkibart Biosimilar Monoclonal Antibody (FLT3 Ligand) for Research
Cat No.: GMP-Bios-INN-1066
Anti-FLT3LG therapeutic antibody (Pre-made Adezkibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Adezkibart (development codes VIB-1116/AMG 329) is a human monoclonal antibody targeting FLT3 ligand (FLT3LG). It is developed by Amgen for autoimmune rheumatic diseases. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1066-1mg | 1mg | 3090 |
| GMP-Bios-INN-1066-10mg | 10mg | |
| GMP-Bios-INN-1066-100mg | 100mg | |
| GMP-Bios-INN-1066-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Adezkibart biosimilar, Whole mAb, Anti-FLT3LG Antibody: Anti-FLT3 Ligand/NeutraControl FLT3 Ligand/NeutraKine FLT3 Ligand/FLT3LG therapeutic antibody |
| INN Name | Adezkibart |
| Target | FLT3LG |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
